Boster Immunoleader

antibody

Anti-CBL Antibody

PB9077

100 ug/vial

240 USD

polyclonal

rabbit

Anti-CBL Antibody

PB9077

Polyclonal

Rabbit IgG polyclonal antibody for E3 ubiquitin-protein ligase CBL(CBL) detection. Tested with WB in Human.

240 USD

Rabbit IgG

100 ug/vial

Lyophilized

No cross reactivity with other proteins.

Reacts with: human

WB

Concentration: 0.1-0.5μg/ml; Tested Species: Human

WB: The detection limit for CBL is approximately 0.25ng/lane under reducing conditions. Tested Species: In-house tested species with positive results. Other applications have not been tested. Optimal dilutions should be determined by end users.

E.coli-derived human CBL recombinant protein (Position: A556-T906). Human CBL shares 84% amino acid (aa) sequence identity with mouse CBL.

Each vial contains 5mg BSA, 0.9mg NaCl, 0.2mg Na2HPO4, 0.05mg NaN3.

Immunogen affinity purified.

Add 0.2ml of distilled water will yield a concentration of 500ug/ml.

At -20˚C for one year. After reconstitution, at 4˚C for one month. It can also be aliquotted and stored frozen at -20˚C for a longer time. Avoid repeated freezing and thawing.

Boster provides a series of assays reacted with primary antibodies. Antibody can be supported by chemiluminescence kit EK1002 in WB.

CBL(Cbl proto-oncogene) is also known as C-CBL, RNF55, CBL2 and E3 ubiquitin protein ligase. CBL is mapped to chromosome 11q23.3-qter by molecular characterization of the breakpoints in 2 somatic cell hybrids. The encoded protein is one of the enzymes required for targeting substrates for degradation by the proteasome. This protein mediates the transfer of ubiquitin from ubiquitin conjugating enzymes(E2) to specific substrates. This protein also contains an N-terminal phosphotyrosine binding domain that allows it to interact with numerous tyrosine-phosphorylated substrates and target them for proteasome degradation. As such it functions as a negative regulator of many signal transduction pathways. This gene has been found to be mutated or translocated in many cancers including acute myeloid leukaemia. Mutations in this gene are also the cause of Noonan syndrome-like disorder.

1. Joazeiro, C. A. P., Wing, S. S., Huang, H., Leverson, J. D., Hunter, T., Liu, Y.-C. The tyrosine kinase negative regulator c-Cbl as a RING-type, E2-dependent ubiquitin-protein ligase. Science 286: 309-312, 1999. 2. Martinelli, S., De Luca, A., Stellacci, E., Rossi, C., Checquolo, S., Lepri, F., Caputo, V., Silvano, M., Buscherini, F., Consoli, F., Ferrara, G., Digilio, M. C., and 14 others.Heterozygous germline mutations in the CBL tumor-suppressor gene cause a Noonan syndrome-like phenotype. Am. J. Hum. Genet. 87: 250-257, 2010. 3. Wei, S., Rocchi, M., Archidiacono, N., Sacchi, N., Romeo, G., Gatti, R. A. Physical mapping of the human chromosome 11q23 region containing the ataxia-telangiectasia locus. Cancer Genet. Cytogenet. 46: 1-8, 1990.

CBL

E3 ubiquitin-protein ligase CBL

Cbl proto-oncogene, E3 ubiquitin protein ligase

4732447J05Rik antibody C CBL antibody Cas Br M (murine) ecotropic retroviral transforming sequence antibody Cas-Br-M (murine) ecotropic retroviral transforming sequence antibody Casitas B lineage lymphoma proto oncogene antibody Casitas B-lineage lymphoma proto-oncogene antibody CBL 2 antibody cbl antibody CBL_HUMAN antibody CBL2 antibody E3 ubiquitin protein ligase CBL antibody E3 ubiquitin-protein ligase CBL antibody Oncogene CBL2 antibody Proto oncogene c CBL antibody Proto-oncogene c-CBL antibody RGD1561386 antibody RING finger protein 55 antibody RNF55 antibody Signal transduction protein CBL antibody

P22681